On September 7, 2015 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), reported that data from 138 abstracts will be presented at this year’s European Cancer Congress (ECC) from Sept. 25 – 29 in Vienna, Austria (Press release, Genentech, SEP 7, 2015, View Source [SID:1234507412]). Results will be presented from several clinical studies that are supporting ongoing regulatory discussions for three investigational medicines across specific types of lung, bladder and skin cancer (alectinib, atezolizumab and cobimetinib, which recently received its first approval in Switzerland where it is marketed as Cotellic). Building on its large portfolio of approved cancer medicines, these regulatory discussions represent significant progress for Genentech’s pipeline in the fields of cancer immunotherapy and targeted medicines.
"With our targeted medicines, cancer immunotherapies and the combination potential in our portfolio, we are committed to setting new standards for treating people with cancer," said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "At the 2015 European Cancer Congress, new data will be presented for three investigational medicines that we hope will be approved within the next year, including atezolizumab for people with PD-L1 expressing lung and bladder cancers."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to data for alectinib, atezolizumab and cobimetinib, results will be presented across multiple tumor types from Genentech’s cancer immunotherapy and targeted medicines pipeline including CEA-IL2v (RG7813), IDO Inhibitor (GDC-0919) and vanucizumab (anti-Ang2/VEGF, RG7221). The table below contains key abstracts featuring Genentech medicines, including late breaking abstracts that will be presented during the Congress.
Follow Genentech on Twitter via @Genentech and keep up to date with the 2015 European Cancer Congress news and updates by using the hashtag #ECC2015.